Development Portfolio

Our development pipeline includes highly attractive product candidates that span important therapeutic areas and that have significant commercial promise. In the first quarter of 2012, we received notification of the approval of Tramadol for use in the treatment of moderate-to-severe pain. In the third quarter of 2014, the China Food and Drug Administration approved the registration of DC Bead(R) for the embolization of malignant hypervascularized tumors. We look forward to advancing additional pipeline products, including DC Bead as the next product in line to potentially receive approval.

China Pipeline HighlightsChina Pipeline Highlights